The transition of the melanoma MART-1neg/NGFRhigh subpopulation to the MART-1neg/NGFRneg subpopulation [78,79], or the transition of from NRASWT/BRAFV600E to NRASG13R/BRAFV600E [80] following treatment with BRAF inhibitors, has also been reported. Here, BRAF is linked to melanoma.